logo
Share SHARE
FONT-SIZE Plus   Neg

Pfizer Unit Reaches Patent Litigation With Intelliject, Sanofi-Aventis

Mylan Inc. (MYL) and Pfizer Inc. (PFE) Thursday announced that Meridian Medical Technologies, a Pfizer subsidiary, has agreed with Intelliject and Sanofi-Aventis to resolve pending patent litigation related to Intelliject's new drug application for its epinephrine auto-injector known as e-cue.

E-cue will be manufactured and marketed by Sanofi-Aventis. Meridian manufactures EpiPen Auto-Injector and Mylan Specialty markets and distributes the product in the United States.

As per the settlement, Intelliject and Sanofi-Aventis may launch e-cue no earlier than November 15, 2012, subject to receipt of final approval from the U.S. Food and Drug Administration.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Oil company Exxon Mobil Corp. on Friday reported a 59 percent fall in profit for the second quarter from last year, while Chevron Corp. reported a loss for the quarter, both on lower revenues. The results of both companies were impacted by the low crude oil and natural gas prices as well as weaker refining margins. Merck & Co Inc. (MRK) reported a second-quarter profit that climbed 75 percent from last year, while quarter sales rose 1 percent. The prior year result included foreign exchange losses of $715 million related to the devaluation of the company's net monetary assets in Venezuela. The company raised the bottom end of its full-year 2016 non-GAAP earnings per share outlook. Xerox (XRX) reported second-quarter adjusted EPS of $0.30, a 7 cent increase over the same period last year driven by a lower tax rate, fewer shares, and higher operating profits. On average, 11 analysts polled by Thomson Reuters expected the company to report profit per share of $0.25 for the quarter....
comments powered by Disqus
Follow RTT